Veru (FRA:FMW0) Notes Receivable: €0.00 Mil (As of Mar. 2026)


FRA:FMW0 Veru Inc FRA:FMW0
32 GF Score
Price €3.44
! 2 Warning Signs
View Full Analysis

What is Veru Notes Receivable?

Veru FRA:FMW0 32 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:FMW0 with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Veru's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

Veru Notes Receivable Historical Data

* Premium members only.

The historical data trend for Veru's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veru Notes Receivable Chart

Veru Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.25 0.00 0.00 0.00 0.00

Veru Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:FMW0
32GF Score
Veru Inc FRA:FMW0
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veru Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Veru (FRA:FMW0) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Veru and its competitors.
Is Veru's Notes Receivable too high?
Veru's current Notes Receivable is €0.00 Mil. Overall, Veru has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Veru's Notes Receivable compare to AURX and PDSB?
Veru's Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Veru and its competitors. Veru's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veru stock overvalued right now?
Veru (FRA:FMW0) has a current Notes Receivable of €0.00 Mil. The current Notes Receivable is €0.00 Mil. Veru's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Veru (FRA:FMW0), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veru Business Description

Other Exchanges VERU:USA
Address 2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
32GF Score

Get the complete analysis for FRA:FMW0

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.44
Price